CONMED Corporation CNMD

LARGO, Fla., October 01, 2026--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the third quarter 2026 after the market close on Wednesday, October 28, 2026. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results.

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason, and a low valuation can reflect underlying business challenges rather than a genuine bargain.

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.

LARGO, Fla., August 26, 2026--CONMED Corporation (NYSE: CNMD) today announced its participation in the Wells Fargo 21st Annual Healthcare Conference, which is being held September 8-10, 2026 at the Encore Boston Harbor in Everett, MA.

CONMED has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 11% to $51.11 per share while the index has gained 10.9%.

Recently, CONMED Corporation was highlighted for its positioning in differentiated surgical platforms such as AirSeal, Buffalo Filter, and BioBrace, with these products benefiting from supportive regulatory trends and growing clinical adoption, while the company continues to face risks from tariffs and slower expansion in specific platforms like AirSeal. An interesting angle is that regulatory momentum around operating room air quality and clinician willingness to adopt newer biomaterials...

What Is Driving Fresh Interest In CONMED Stock Today CONMED (CNMD) is back in focus as investors assess the adoption of its AirSeal, Buffalo Filter, and BioBrace platforms, along with tariff headwinds and slower AirSeal growth, in the context of the company’s broader earnings profile. See our latest analysis for CONMED. CONMED’s share price has moved to US$49.25 after a strong 30 day share price return of 14% and a 90 day share price return of 36.12%. However, the 1 year total shareholder...

CONMED's growth outlook is supported by Buffalo Filter, BioBrace and organic momentum, though slower AirSeal growth and tariffs remain key risks.

Check out the companies making headlines this week:

Shares of medical tech company CONMED (NYSE:CNMD) jumped 10.5% in the afternoon session after the company reported second-quarter adjusted earnings that beat analyst expectations and raised its full-year guidance.